China Life Insurance (SEHK:2628) drew fresh attention after issuing first half 2026 earnings guidance, projecting net profit of RMB 128,933 million to RMB 137,119 million, implying a year-on-year increase of about 215% to 235%.
See our latest analysis for China Life Insurance.
Following the guidance, China Life Insurance is trading at HK$27.46, with the share price down over the year to date but supported by a 1 year total shareholder return of 36.16% and very large 3 and 5 year total shareholder returns. This suggests that longer term momentum has been far stronger than the recent pullback.
If this kind of earnings guidance has you thinking about where else returns might be building, it could be a good time to scan for 108 top founder-led companies
After that strong profit guidance and a share price that has slipped year to date yet delivered very large multi year returns, does China Life Insurance still offer a favourable balance of upside and risk at today’s valuation?
Most Popular Narrative: 21% Undervalued
Compared with the last close at HK$27.46, the most followed narrative points to a fair value of HK$34.77, using a 7.12% discount rate and detailed earnings assumptions.
The analysts have a consensus price target of HK$34.77 for China Life Insurance based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of HK$44.61, and the most bearish reporting a price target of just HK$14.01.
Want to see what justifies that gap between current price and fair value for China Life Insurance? Revenue growth, margin resets and a future earnings multiple all sit at the core of this narrative, and the exact mix of those inputs may surprise you.
Result: Fair Value of HK$34.77 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, China Life Insurance still faces pressure if investment income normalises or the sales force transformation fails to lift productivity, which could challenge the current undervalued narrative.
Find out about the key risks to this China Life Insurance narrative.
Next Steps
With China Life Insurance generating both optimism and concern, this is a good moment to review the numbers yourself and weigh the trade off between upside and risk using 4 key rewards and 1 important warning sign
Looking for more investment ideas beyond China Life Insurance?
Once you have weighed up China Life Insurance, do not stop there. Broaden your opportunity set with a few targeted stock ideas built from powerful data screens.
- Spot potential value opportunities early by reviewing companies flagged in the 233 high quality undervalued stocks.
- Strengthen your focus on resilience by scanning stocks in the 294 resilient stocks with low risk scores.
- Hunt for off-the-radar opportunities by checking the screener containing 512 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com